Administration of recombinant tPA (rtPA, or trade name Alteplase®) is an FDA-approved
therapy for
acute ischemic stroke (AIS), but poses the risk of hemorrhagic complications. Recombinant tPA can be rapidly inactivated by the endogenous
inhibitor, plasminogen activator inhibitor 1 (PAI-1). In this work, we study a novel treatment approach that combines a
PAI-1 inhibitor, PAItrap4, with a reduced dose of rtPA to address the hemorrhagic concern of rtPA. PAItrap4 is a highly specific and very potent
protein-based inhibitor of
PAI-1, comprising of a variant of uPA
serine protease domain,
human serum albumin, and a
cyclic RGD peptide. PAItrap4 efficiently targets and inhibits
PAI-1 on activated platelets, and also possesses a long half-life in vivo. Our results demonstrate that PAItrap4 effectively counteracts the inhibitory effects of
PAI-1 on rtPA, preserving rtPA activity based on amidolytic and clot lysis assays. In an in vivo murine
stroke model, PAItrap4, together with low-dose rtPA, enhances the blood perfusion in the
stroke-affected areas, reduces
infarct size, and promotes neurological recovery in mice. Importantly, such treatment does not increase the amount of
cerebral hemorrhage, thus reducing the risk of
cerebral hemorrhage. In addition, PAItrap4 does not compromise the normal blood coagulation function in mice, demonstrating its safety as a therapeutic agent. These findings highlight this combination
therapy as a promising alternative for the treatment of
ischemic stroke, offering improved safety and efficacy.